Filter posts

#BIO2017: What's Happening in the World of IP?

Who’s ready to hit the beach? Wait, did I say beach? I meant the San …

Registration for BIO's Spring IP Counsels Committee Conference is now OPEN!

Tired of those pea-coats and earmuffs? Wish you were lying on a beach right now, …

WSJ: U.S. Concessions on TPP Means Fewer Cures

Today’s Wall Street Journal editorial, Pacific Trade Brinksmanship, does an outstanding job highlighting the important …

FDA Acts on Biosimilars

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration …

Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?

In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first …

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Biosimilars raise novel and complex questions of science and law that require updated legal and …

Pitts Sounds off on Biosimilar Naming

This week, the Food and Drug Law Institute published a white paper – Biosimilar Nomenclature: …

Docs to FDA: Biosimilars should have different names than branded drugs

Yesterday, Fierce Biotech highlighted a letter written by more than 10 medical associations and 20 individual specialists …

Ensuring the Safety and Commercial Success of Biosimilars in the United States

The forthcoming arrival of biosimilars into the U.S has spurred debate over the approaches that …

BIO Recognizes the Work of Two Indiana Legislators

Across the country state lawmakers are addressing the issue of biosimilars, lower-cost biologic medicines that …